KR20090042976A - 글루코즈 수준을 저하시키는 방법 - Google Patents

글루코즈 수준을 저하시키는 방법 Download PDF

Info

Publication number
KR20090042976A
KR20090042976A KR1020097005581A KR20097005581A KR20090042976A KR 20090042976 A KR20090042976 A KR 20090042976A KR 1020097005581 A KR1020097005581 A KR 1020097005581A KR 20097005581 A KR20097005581 A KR 20097005581A KR 20090042976 A KR20090042976 A KR 20090042976A
Authority
KR
South Korea
Prior art keywords
ramipril
patient
glucose
disease
impaired
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020097005581A
Other languages
English (en)
Korean (ko)
Inventor
헤첼 거스타인
살림 유서프
Original Assignee
사노피-아벤티스 도이칠란트 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사노피-아벤티스 도이칠란트 게엠베하 filed Critical 사노피-아벤티스 도이칠란트 게엠베하
Publication of KR20090042976A publication Critical patent/KR20090042976A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
KR1020097005581A 2006-08-28 2007-08-14 글루코즈 수준을 저하시키는 방법 Ceased KR20090042976A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84085006P 2006-08-28 2006-08-28
US60/840,850 2006-08-28

Publications (1)

Publication Number Publication Date
KR20090042976A true KR20090042976A (ko) 2009-05-04

Family

ID=38578487

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097005581A Ceased KR20090042976A (ko) 2006-08-28 2007-08-14 글루코즈 수준을 저하시키는 방법

Country Status (12)

Country Link
US (1) US20080188538A1 (enExample)
EP (1) EP2059242A1 (enExample)
JP (1) JP2010501604A (enExample)
KR (1) KR20090042976A (enExample)
CN (1) CN101573110A (enExample)
AU (1) AU2007291602B2 (enExample)
BR (1) BRPI0716411A2 (enExample)
CA (1) CA2661598A1 (enExample)
IL (1) IL197189A0 (enExample)
MX (1) MX2009002091A (enExample)
NO (1) NO20090926L (enExample)
WO (1) WO2008025450A1 (enExample)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA817261B (en) * 1980-10-23 1982-09-29 Schering Corp Carboxyalkyl dipeptides,processes for their production and pharmaceutical compositions containing them
DE3226768A1 (de) * 1981-11-05 1983-05-26 Hoechst Ag, 6230 Frankfurt Derivate der cis, endo-2-azabicyclo-(3.3.0)-octan-3-carbonsaeure, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung
DE3413710A1 (de) * 1984-04-12 1985-10-24 Hoechst Ag, 6230 Frankfurt Verfahren zur behandlung der herzinsuffizienz
DE3739690A1 (de) * 1987-11-24 1989-06-08 Hoechst Ag Stabilisierte arzneistoffe, verfahren zu ihrer herstellung sowie stabile arzneizubereitungen
CA2026686A1 (en) * 1989-10-30 1991-05-01 Werner Tschollar Method for preventing onset of type ii diabetes employing an ace inhibitor
SE9903028D0 (sv) * 1999-08-27 1999-08-27 Astra Ab New use
ATE303800T1 (de) * 1999-08-30 2005-09-15 Aventis Pharma Gmbh Ramipril zur vorbeugung von kardiovaskulären vorfällen
US20050065203A1 (en) * 2001-10-17 2005-03-24 Salim Yusuf Method of reducing type 2 diabetes in high risk patients
JP2005531492A (ja) * 2001-10-17 2005-10-20 アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 高リスク患者のｉｉ型糖尿病を低減させる方法
WO2004080482A2 (en) * 2003-03-11 2004-09-23 Institut De Cardiologie De Montréal / Use of angiotensin converting enzyme (ace) inhibitors to prevent diabetes in a subject with chronic heart failure

Also Published As

Publication number Publication date
JP2010501604A (ja) 2010-01-21
AU2007291602A1 (en) 2008-03-06
MX2009002091A (es) 2009-03-09
IL197189A0 (en) 2009-12-24
NO20090926L (no) 2009-03-27
CA2661598A1 (en) 2008-03-06
WO2008025450A1 (en) 2008-03-06
BRPI0716411A2 (pt) 2013-09-24
EP2059242A1 (en) 2009-05-20
US20080188538A1 (en) 2008-08-07
AU2007291602B2 (en) 2012-09-06
CN101573110A (zh) 2009-11-04

Similar Documents

Publication Publication Date Title
Scott et al. Esomeprazole: a review of its use in the management of acid-related disorders
KR102271048B1 (ko) 콜히친의 서방형 제형 및 이의 이용 방법
CN101534798B (zh) 包含噻嗪类和血管紧张素ⅱ受体阻断剂的控释药物组合物
JP6125567B2 (ja) ニトライトの医薬製剤及びそれらの使用
CN106109469A (zh) 保护血管及保护心脏的抗糖尿病性治疗
BRPI0719969A2 (pt) Preparação combinada para o tratamento de doenças cardiovasculares com base em teoria de cronoterapia.
RU2672248C1 (ru) Применение производного бензимидазола для лечения ночного кислотного прорыва
CN107157999A (zh) 川芎嗪硝酮衍生物在预防和治疗糖尿病并发症疾病中的应用
MD3684344T2 (ro) Comprimate de deferipronă cu eliberare întârziată și metode de utilizare a acestora
EP2296665A2 (en) Pharmaceutical composition for the treatment of premature ejaculation
TW200843741A (en) Pharmaceutical composition
EP2837380B1 (en) Lercanidipine hydrochloride and losartan potassium compound preparation and preparation method thereof
US7271146B2 (en) Methods for treatment of Helicobacter pylori-associated disorders
CA2563325C (en) Oral modified-release lozenges and their preparation method
WO2005070427A1 (en) Compounds for the sustained reduction of body weight
KR20120089787A (ko) 염산레르카니디핀 및 발사르탄을 포함하는 복합 제제 및 이의 제조방법
KR20090042976A (ko) 글루코즈 수준을 저하시키는 방법
TWI867128B (zh) 前列腺環素衍生物用於製造用以抑制轉入透析或腎死之藥劑之用途
JP2007513991A (ja) メタボリック症候群の処置のためのスタチンの使用
CA3221017A1 (en) Pharmaceutical composition comprising 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid
FI4032530T3 (fi) Pidennetysti vapautuva furatsidiinikoostumus
JP2006076956A (ja) 胃炎の治療・予防用配合剤
HK1138182A (en) Methods of lowering glucose levels
KR100709531B1 (ko) 당뇨병성 합병증의 예방 또는 진전저지용 의약조성물
Çetin Fixed-dose combination-orally disintegrating tablet (FDC-ODT) studies for the treatment of type 2 diabetes or cardiovascular diseases-a mini review

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20090318

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20120813

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20131029

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20140312

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20131029

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I